Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tropifexor

- PMLiVE

Novartis’ Leqvio shows sustained efficacy and safety for cardiac patients

Low-density lipoprotein cholesterol level reduction was sustained over four years

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

One to two people per million are diagnosed with paroxysmal nocturnal haemoglobinuria each year

- PMLiVE

Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma

The decision is based on results from the phase 2 ZUMA-7 study

- PMLiVE

Novartis bags CHMP recommendation for prostate cancer drug Pluvicto

The recommendation is for use in combination with androgen deprivation therapy

- PMLiVE

Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer

Phase 2 study results showed a 34% reduction in risk of disease progression or death

- PMLiVE

Novartis announces $300m investment to boost development of next-generation biotherapeutics

The multi-year investment will be implemented across the company’s existing locations in Switzerland, Slovenia and Austria

- PMLiVE

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Hepatocellular carcinoma accounts for 75-85% of liver cancer diagnoses

- PMLiVE

Novartis and Kaiku Health expand digital health monitoring partnership

The expansion aims to provide improved cancer care to a wider group of patients spanning multiple indications

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported

A data review found that branaplam may cause peripheral neuropathy, which is the result of nerve injury outside the brain and spinal cord

- PMLiVE

Novartis to separate generic drugs division Sandoz to create standalone company

The spin-off will allow shareholders to participate fully in the potential future upside of both companies

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links